【摘要】 目的:评价国产新福菌素对老年非小细胞肺癌(NSCLC)的疗效和不良反应。方法:选取老年NSCLC病例81例,随机分治疗组43例给予新福菌素6μg/kg(第1~4d),卡铂(CBP)300mg/m2(第1d),依托泊苷(VP-16)100mg(第1~4或5d)静脉滴注;对照组38例单纯使用CBP和VP-16,剂量和方法同治疗组,21~28d为一个疗程,2~3个疗程评价疗效,随访缓解期和生存期。结果:治疗组有效率为53·49%,对照组有效率为31·58%,差异有显著性(P<0·05);中位缓解期分别为6和4·5个月,中位生存期分别为9和7个月,一年生存率分别为39·53%(17/43)和26·32%(10/38)。结论:新福菌素联合CBP、VP-16治疗老年NSCLC有较好的临床疗效及应用价值。更多还原

【Abstract】 Objective:To investigate the curative effects and side-effect of domestic drug-Sinoactionomycin in treating elderly non-small cell lung cancer (NSCLC).Methods: 81 cases with elderly NSCLC were divided into two groups randomly,43 cases in the treatment group were administrated with Sinoactionomycin 6g/kg (1~4 day) combining card platinum (CBP) 300mg/m~ 2 (1st day), glucoside (VP-16) 100 mg (1~4 or 5 days) intravenously.38 cases in the control group were only treated with CBP and vp-16 and the dosage were same with that of treatment group.21~28 days were taken as a treatment cycle and the curative effects were studied after 2~3 cycles.The relievable and survival periods were investigated as well.Results: The effectiveness for treatment troup is 53.49%, effectiveness for control group is 31.58%, the difference has the significance (P<0.05); The central relievable period is 6 and 4.5 months respectively, and the central survival period is 9 and 7 months respectively,on year survival rate respectively is 39.53% (17,/43) and 26.32% (10,/38). Conclusion: Sinoactionomycin combining CBP,and VP-16 has good clinical curative effect in treating elderly NSCLC and has the good clinical practice value.更多还原